DE69736928D1 - Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus - Google Patents

Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus

Info

Publication number
DE69736928D1
DE69736928D1 DE69736928T DE69736928T DE69736928D1 DE 69736928 D1 DE69736928 D1 DE 69736928D1 DE 69736928 T DE69736928 T DE 69736928T DE 69736928 T DE69736928 T DE 69736928T DE 69736928 D1 DE69736928 D1 DE 69736928D1
Authority
DE
Germany
Prior art keywords
agonist
glucose metabolism
fat
composition
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736928T
Other languages
English (en)
Other versions
DE69736928T2 (de
Inventor
H Cincotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veroscience LLC
Original Assignee
Pliva Hrvatska doo
Pliva Istrazivanje i Razvoj doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Hrvatska doo, Pliva Istrazivanje i Razvoj doo filed Critical Pliva Hrvatska doo
Application granted granted Critical
Publication of DE69736928D1 publication Critical patent/DE69736928D1/de
Publication of DE69736928T2 publication Critical patent/DE69736928T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
DE69736928T 1996-05-07 1997-05-06 Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus Expired - Lifetime DE69736928T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1737796P 1996-05-07 1996-05-07
US17377P 1996-05-07
US1933696P 1996-06-06 1996-06-06
US19336P 1996-06-06
PCT/US1997/007701 WO1997041873A1 (en) 1996-05-07 1997-05-06 Method and composition for the treatment of lipid and glucose metabolism disorders

Publications (2)

Publication Number Publication Date
DE69736928D1 true DE69736928D1 (de) 2006-12-21
DE69736928T2 DE69736928T2 (de) 2007-06-28

Family

ID=26689794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736928T Expired - Lifetime DE69736928T2 (de) 1996-05-07 1997-05-06 Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus

Country Status (9)

Country Link
EP (2) EP1776955B1 (de)
AT (1) ATE344668T1 (de)
CA (1) CA2254116C (de)
DE (1) DE69736928T2 (de)
DK (1) DK0934069T3 (de)
ES (2) ES2277357T3 (de)
HK (1) HK1108312A1 (de)
PT (1) PT934069E (de)
WO (1) WO1997041873A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6366298B1 (en) 1999-06-03 2002-04-02 Netzero, Inc. Monitoring of individual internet usage
US9655865B2 (en) * 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP1870096A3 (de) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Zusammensetzungen zur Beeinflussung von Gewichtsverlust
EP2316456B1 (de) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Zubereitungen enthaltend einen Opioidantagonisten und Bupropion zur Beeinflussung von Gewichtsverlust
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
AU2013263800B2 (en) * 2007-03-30 2016-05-05 Veroscience Llc Methods of treating metabolic syndrome using dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
WO2009062113A1 (en) * 2007-11-07 2009-05-14 Burnham Institute For Medical Research Method and compounds for modulating insulin production
AU2015201255B2 (en) * 2008-01-14 2016-05-19 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
EP4104824A1 (de) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Zusammensetzung zur verwendung in einem verfahren zur behandlung von übergewicht und fettleibigkeit bei patienten mit hohem kardiovaskulärem risiko
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3419293A (en) * 1991-12-23 1993-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The A therapeutic process for the treatment of the pathologies of type II diabetes

Also Published As

Publication number Publication date
DE69736928T2 (de) 2007-06-28
EP0934069A1 (de) 1999-08-11
EP0934069B1 (de) 2006-11-08
CA2254116C (en) 2009-10-20
EP1776955B1 (de) 2012-08-15
EP1776955A1 (de) 2007-04-25
ES2393303T3 (es) 2012-12-20
DK0934069T3 (da) 2007-03-19
WO1997041873A1 (en) 1997-11-13
CA2254116A1 (en) 1997-11-13
HK1108312A1 (en) 2008-05-02
PT934069E (pt) 2007-02-28
EP0934069A4 (de) 2002-12-04
ATE344668T1 (de) 2006-11-15
ES2277357T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
DE69736928D1 (de) Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
DE69527847T2 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
NO2015027I1 (no) Mepolizumab
ATE362361T1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69404039D1 (de) Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
ES2184111T3 (es) Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor.
ATE218330T1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
DE59700768D1 (de) Verfahren zur behandlung von cellulosefasern und von gebilden aus diesen fasern
DE59703792D1 (de) Verfahren zur gewinnung von glykolen mit niedrigem aldehydgehalt
ATE37141T1 (de) Haarkurmittel und verfahren zur haarbehandlung.
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
ATE205896T1 (de) Verfahren zur behandlung von wolle
ATE291909T1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
DE60017793D1 (de) Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE69418345D1 (de) Verfahren zur stabilisierung von pvdc enthaltenden polyolefinmischungen und stabilisierte pvdc enthaltende polyolefinmischungen
ATE228590T1 (de) Verfahren zur behandlung von cellulosefasern
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE179603T1 (de) Pharmazeutische zusammensetzung zur behandlung der zerebralthrombose
UA29250A (uk) Спосіб дії на пласт та глушіння свердловин

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: VEROSCIENCE LLC,(N.D.GES.D.STAATES DELAWARE),,, US

8364 No opposition during term of opposition